Qiang Yu

List of Publications by Year
in descending order

72 papers	7,342 citations	94269 37 h-index	88477 70 g-index
72 all docs	72 docs citations	72 times ranked	13076 citing authors

#	Article	IF	Citations
1	A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome. Cell, 2006, 124, 207-219.	13.5	1,060
2	Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes and Development, 2007, 21, 1050-1063.	2.7	804
3	Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis. Cell, 2012, 148, 259-272.	13.5	593
4	Context-Specific Regulation of NF-Îºb Target Gene Expression by EZH2 in Breast Cancers. Molecular Cell, 2011, 43, 798-810.	4.5	338
5	miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRbâ€“E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes and Development, 2009, 23, 2388-2393.	2.7	242
6	Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16090-16095.	3.3	234
7	Methionine is a metabolic dependency of tumor-initiating cells. Nature Medicine, 2019, 25, 825-837.	15.2	226
8	DACT3 Is an Epigenetic Regulator of Wnt/Î²-Catenin Signaling in Colorectal Cancer and Is a Therapeutic Target of Histone Modifications. Cancer Cell, 2008, 13, 529-541.	7.7	216
9	The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood, 2011, 118, 2830-2839.	0.6	205
10	Hypoxic tumor microenvironment activates GLI2 via HIF-1Î± and TGF-Î²2 to promote chemoresistance in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5990-E5999.	3.3	203
11	CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells. PLoS ONE, 2009, 4, e5011.	1.1	155
12	p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis. Journal of Biological Chemistry, 2004, 279, 21183-21192.	1.6	133
13	EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood, 2013, 121, 4512-4520.	0.6	131
14	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 2015, 6, 8746.	5.8	125
15	PDK1 Signaling Toward PLK1â€“MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy. Cancer Discovery, 2013, 3, 1156-1171.	7.7	119
16	Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nature Medicine, 2017, 23, 1319-1330.	15.2	116
17	Pharmacologic Modulation of Glycogen Synthase Kinase-3Î² Promotes p53-Dependent Apoptosis through a Direct Bax-Mediated Mitochondrial Pathway in Colorectal Cancer Cells. Cancer Research, 2005, 65, 9012-9020.	0.4	115
18	UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Research, 2002, 62, 5743-8.	0.4	115

#	Article	IF	Citations
19	VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discovery, 2017, 7, 1284-1305.	7.7	111
20	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood, 2016, 128, 948-958.	0.6	110
21	Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget, 2018, 9, 33416-33439.	0.8	107
22	B55Î²-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer. Cancer Cell, 2010, 18, 459-471.	7.7	104
23	BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Research, 2009, 11, R63.	2.2	98
24	TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms. International Journal of Biochemistry and Cell Biology, 2011, 43, 1668-1673.	1.2	94
25	EZH2-Mediated Inactivation of IFN-Î³-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. Cell Reports, 2014, 8, 204-216.	2.9	87
26	RASAL2 activates RAC1 to promote triple-negative breast cancer progression. Journal of Clinical Investigation, 2014, 124, 5291-5304.	3.9	72
27	Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy. Drug Resistance Updates, 2006, 9, 19-25.	6.5	71
28	Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. Journal of Clinical Investigation, 2017, 127, 3689-3701.	3.9	71
29	Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Molecular Cancer Therapeutics, 2009, 8, 3191-3202.	1.9	65
30	TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). Clinical Cancer Research, 2012, 18, 4201-4212.	3.2	65
31	Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Letters, 2001, 505, 7-12.	1.3	62
32	HIFI-Î± activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3735-44.	3.3	62
33	Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity. Journal of Biological Chemistry, 2006, 281, 10508-10515.	1.6	60
34	The E2F family and the role of E2F1 in apoptosis. International Journal of Biochemistry and Cell Biology, 2009, 41, 2389-2397.	1.2	57
35	Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11121-11126.	3.3	57
36	Ribosomal Protein S27-like, a p53-Inducible Modulator of Cell Fate in Response to Genotoxic Stress. Cancer Research, 2007, 67, 11317-11326.	0.4	56

#	Article	IF	Citations
37	Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer. Nature Communications, 2021, 12, 4441.	5.8	49
38	Hypoxia induces HIF1Î±-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nature Communications, 2022, 13, .	5.8	48
39	Dual Regulation of Cdc25A by Chk1 and p53-ATF3 in DNA Replication Checkpoint Control. Journal of Biological Chemistry, 2009, 284, 4132-4139.	1.6	38
40	Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling. Cell Death and Disease, 2022, 13, 16.	2.7	36
41	miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle, 2010, 9, 213-214.	1.3	35
42	Elevated expression of long intergenic nonâ€coding RNA HOTAIR in a basalâ€like variant of MCFâ€7 breast cancer cells. Molecular Carcinogenesis, 2015, 54, 1656-1667.	1.3	35
43	KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer. Molecular Cancer Therapeutics, 2018, 17, 1973-1983.	1.9	35
44	Heterogeneous epigenetic regulation ofTIMP3in prostate cancer. Epigenetics, 2012, 7, 1279-1289.	1.3	34
45	KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. Journal of Experimental Medicine, 2018, 215, 2833-2849.	4.2	33
46	MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in MetastaticÂMelanoma. Journal of Investigative Dermatology, 2017, 137, 1955-1964.	0.3	32
47	Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chinese Journal of Cancer, 2013, 32, 376-379.	4.9	32
48	Two COOH-Terminal Truncated Cytoplasmic Forms of Topoisomerase IIÎ± in a VP-16-Selected Lung Cancer Cell Line Result from Partial Gene Deletion and Alternative Splicingâ€. Biochemistry, 1997, 36, 5868-5877.	1.2	30
49	Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells. PLoS ONE, 2011, 6, e21583.	1.1	29
50	Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlusâ„¢. European Journal of Pharmaceutical Sciences, 2015, 77, 290-302.	1.9	29
51	EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy. Nature Communications, 2020, 11, 5878.	5.8	29
52	Inhibition of the PLK1â€Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Advanced Science, 2021, 8, e2100759.	5.6	29
53	Identification of Myc-mediated Death Response Pathways by Microarray Analysis. Journal of Biological Chemistry, 2002, 277, 13059-13066.	1.6	27
54	The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy. PLoS ONE, 2014, 9, e107817.	1.1	27

#	Article	IF	Citations
55	3â€Deazaneplanocinâ€...A and Neplanocinâ€...A Analogues and Their Effects on Apoptotic Cell Death. ChemMedChem, 2015, 10, 173-182.	1.6	24
56	c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. International Journal of Biochemistry and Cell Biology, 2007, 39, 1016-1025.	1.2	21
57	A truncated cytoplasmic topoisomerase IIÎ± in a drug-resistant lung cancer cell line is encoded by aTOP2A allele with a partial deletion of exon 34. , 2000, 85, 534-539.		20
58	Targeting the IRAK1â€“S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research, 2021, 81, 1413-1425.	0.4	19
59	Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS ONE, 2015, 10, e0122983.	1.1	18
60	Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acidâ€“drug complex and its pharmacokinetic features in Sprague–Dawley rats. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 323-331.	2.0	15
61	HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. Cell Cycle, 2019, 18, 1513-1522.	1.3	15
62	Intrahepatic biliary cystadenocarcinoma: clinical analysis of 4 cases. Hepatobiliary and Pancreatic Diseases International, 2009, 8, 71-4.	0.6	12
63	CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Letters, 2021, 521, 268-280.	3.2	10
64	Cancer gene silencing without DNA hypermethylation. Epigenetics, 2008, 3, 315-317.	1.3	8
65	Interleukin enhancerâ€binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. Clinical and Translational Medicine, 2021, 11, e608.	1.7	8
66	Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatographyâ€“tandem mass spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 285-290.	1.2	7
67	Molecular switch of EZH2 in hypoxia. Cell Cycle, 2016, 15, 3007-3008.	1.3	6
68	Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	6
69	Tumor Necrosis Factor-Î± and Apoptosis Induction in Melanoma Cells through Histone Modification by 3-Deazaneplanocin A. Journal of Investigative Dermatology, 2014, 134, 1470-1473.	0.3	3
70	Herbal compound Naoshuantong capsule attenuates retinal injury in ischemia/reperfusion rat model by inhibiting apoptosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 12252-63.	1.3	3
71	PDK1-driven Myc signaling regulates cellular response to mTOR inhibitors. Cell Cycle, 2011, 10, 1019-1020.	1.3	1
72	Systems Pharmacology in Cancer. , 2010, , 377-397.		0